Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have provided informed consent prior to any study specific procedures.~* Participants currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR) criteria for schizophrenia.~* Participants with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG).~* Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (Screening).~* Positive and Negative Syndrome Scale (PANSS) total score ≥ to 70 and ≤ 120 at Visit 1 (Screening) and Visit 2 (beginning of Run-in Phase).~* Negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test (applies to female participants of childbearing potential only).~* Body mass index between 18 and 40 kg/m\^2, inclusive.~Exclusion Criteria:~* Participants currently meeting DSM-IV-TR criteria for schizoaffective disorder, schizophreniform disorder, bipolar I and II and known or suspected borderline or antisocial personality disorder. or other DSM-IV-TR axis II disorders.~* Participants in their first episode of psychosis.~* Treatment-resistant schizophrenia over the last 2 years.~* Positive result from the blood alcohol test or from the urine drug screen for any prohibited medication.~* At imminent risk of injuring self or others or causing significant damage to property.~* Suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine - Open-label Phase (Type: EXPERIMENTAL): Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
- Placebo - Double-blind Treatment Phase (Type: EXPERIMENTAL): Participants received placebo orally once a day for 26 to 72 weeks.
- Cariprazine - Double-blind Treatment Phase (Type: EXPERIMENTAL): Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).